Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | ACHE | P22303 | 4/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | DRD3 | P35462 | 5/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345517 | 0.88 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8074259 | 0.88 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8603749 | 0.88 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8076218 | 0.87 | CA1 (0.59) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL9361122 | 0.87 | CA1 (0.55) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8066286 | 0.87 | CA1 (0.59) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8603697 | 0.87 | CA1 (0.59) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8076235 | 0.87 | CA1 (0.55) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL9361562 | 0.87 | CA1 (0.55) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL346286 | 0.84 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178781-A1 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173678-B2 | Kappa opioid receptor ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2012-05-08 | — | — | US | disclosed |
| EP-1848275-B1 | KAPPA OPIOID RECEPTOR LIGANDS | RES TRIANGLE INST (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20110065743-A1 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2011-03-17 | — | — | US | disclosed |
| US-7872023-B2 | administering 6-Hydroxy-1,2,3,4-tetrahydro-naphthalene-2(-)-carboxylic acid{1-[4-(3-hydroxyphenyl)-(3R)-(4R)-trans-dimethyl-piperidinylmethyl]-(2S)-methylpropyl}-amide, for the treatment of drug abuse and dependence | RESEARCH TRIANGLE INSTITUTE (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1848275-A1 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006089130-A1 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183743-A1 | Kappa opioid receptor ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065743-A1 | KAPPA OPIOID RECEPTOR LIGANDS | OPRK1, OPRD1, OPRM1 | CA1 3185/4885CA2 4530/4885ACHE 929/4885 |
| US-20060183743-A1 | Kappa opioid receptor ligands | OPRK1, OPRD1, OPRM1 | CA1 3185/4885CA2 4530/4885ACHE 929/4885 |
| US-20120178781-A1 | KAPPA OPIOID RECEPTOR LIGANDS | OPRK1, OPRD1, OPRM1 | CA1 3185/4885CA2 4530/4885ACHE 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.